Hulk Stack
Hulk blend · IGF-1 LR3 + CJC-1295 + Ipamorelin · anabolic GH/IGF stack
ANECDOTAL · GH + IGF STACK: GHRH ANALOG + SELECTIVE GHRP + LONG-ACTING IGF-1 ANALOG
Mechanism of action
Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation.
Researched effects
Muscle accrual and recovery support through layered GH + IGF action; reported effects include improved recovery and lean-mass gain during dosing cycles
Dosing reported in literature
Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks
Known concerns
Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved
No references match — clear filters.
Curated sources on file
4- 1.
- 2.
- 3.
-
4.
Note: The Hulk Stack is a community / vendor-marketed three-compound protocol with no published trial of the combination. Evidence is anecdotal; cited papers describe each component separately.